A Phase 3, randomized open-Label study of pembrolizumab plus olaparib vs. abiraterone or enzalutamide in participants with metastatic castrationresistant prostate cancer (mCRPC) who are unselected for homologous recombination repair defects and have failed Prior Treatment with one next-generation hormonal Agent (NHA) and chemotherapy
Hormon,Zielgerichtet
